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Objective: Prior analysis in the Open vs Endovascular Repair Veterans Affairs (VA) Cooperative Study (CSP #498)
demonstrated that survival, quality of life, and total health care costs are not signiﬁcantly different between the open and
endovascular methods of repair of abdominal aortic aneurysm. The device is a major cost of this method of repair, and the
objective of this study was to evaluate the costs of the device, abdominal aortic aneurysm repair, and total health care costs
when different endograft systems are selected for the endovascular repair (EVR). Within each selected system, EVR costs
are compared with open repair costs.
Methods: The study randomized 881 patients to open (n[ 437) or EVR (n[ 444). Device selection was recorded before
randomization; therefore, open repair controls were matched to each device cohort. Data were excluded for two low-
volume devices, implanted in only 13 individuals, leaving 423 control and 431 endovascular patients: 166 Zenith
(Cook Medical, Bloomington, Ind), 177 Excluder (W. L. Gore & Associates, Flagstaff, Ariz), and 88 AneuRx (Med-
tronic, Minneapolis, Minn). Mean device, hospitalization, and total health care costs from randomization to 2 years were
compared. Health care utilization data were obtained from patients and national VA and Medicare data sources. VA costs
were determined using methods previously developed by the VA Health Economics Resource Center. Non-VA costs were
obtained from Medicare claims data and billing data from the patient’s health care providers.
Results: Implant costs were 38% of initial hospitalization costs. Mean device (range, $13,600-$14,400), initial hospi-
talization (range, $34,800-$38,900), and total health care costs at 2 years in the endovascular (range, $72,400-$78,200)
and open repair groups (range, $75,600-$82,100) were not signiﬁcantly different among device systems. Differences
between endovascular and corresponding open repair cohorts showed lower mean costs for EVR (range, $3200-$8300),
but these were not statistically different.
Conclusions: The implant costs of endovascular aneurysm repair are substantial. When evaluating total health care system
expenditures, there is large individual variability in costs, and there is no signiﬁcant difference at 2 years among systems or
when an individual system is compared with open repair. (J Vasc Surg 2015;61:59-65.)Efforts to contain health care costs have gained greater
prominence, and physicians are in a pivotal role of deter-
mining which treatments their patients receive. Endovascu-
lar repair (EVR) of abdominal aortic aneurysms (AAAs) is
particularly visible, with high volume and very high device
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://dx.doi.org/10.1016/j.jvs.2014.08.003The role of new medical technology deserves special attention
in thinking about future health care spending because
biomedical innovations as a whole have been the primary
source of both improvements in health and increasing ex-
penditures. On the one hand, it is ﬁscally irresponsible to
continue to accept innovations regardless of cost, even if
they pass tests of safety and efﬁcacydand it is particularly
irresponsible when the interventions are provided at public
expense. On the other hand, we must avoid an innovation
policy that cuts off new interventions prematurely.1Several randomized trials have demonstrated similar
long-term survival and quality of life when AAAs are elec-
tively repaired by EVR or open methods.2-4 Comparisons
of costs have been evaluated with contrasting results,
with some studies showing cost-effectiveness of EVR, and
others ﬁnding EVR was more costly.2,5-7
The Department of Veterans Affairs (VA) Open vs
Endovascular Repair (OVER) trial (ClinicalTrials.gov num-
ber, NCT00094575) reported a comparison of costs at
2 years between EVR and open repair of AAA. Speciﬁcally,
mean graft costs were higher with EVR ($14,052 vs $1363;
P <.001), but length of stay was shorter (5.0 vs 10.5 days;
P<.001), with the result that themean AAA repair hospital-
ization cost is less with EVR (difference, $5901; 95%59
Table I. Mean and median costs of abdominal aortic aneurysm (AAA) repair by device selected and randomized assignment
Variable Zenitha Excluderb
EVR (n ¼ 431), No. 166 177
Mortality rate, % 6 6
Implant, mean (SD), $ 14,400 (2600) 13,600 (3800)
Initial hospital, mean (SD), $ 38,100 (27,500) 34,800 (31,200)
Total cost at 2 years, $
Mean (SD) 78,200 (60,200) 73,500 (65,100)
Median (IQR) 62,000 (48,000-85,400) 54,100 (39,400-76,300)
Open (n ¼ 423), No. 175 150
Mortality rate, % 9 11
Total cost at 2 years, $
Mean (SD) 82,100 (113,800) 81,800 (84,500)
Median (IQR) 57,000 (36,100-85,400) 56,800 (39,600-88,800)
Difference EVR  open, $ (95% CI) 3900 (27,800 to 11,400) 8300 (27,100 to 6000)
CI, Conﬁdence interval; EVR, endovascular repair; IQR, interquartile range; SD, standard deviation.
aCook Inc, Bloomington, Ind.
bW. L. Gore and Associates, Flagstaff, Ariz.
cMedtronic, Minneapolis, Minn.
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health care costs were not signiﬁcantly lower with EVR (dif-
ference, $5019; 95% CI, $4928 to $16,720).5
We studied device, hospitalization, and total health care
costs when different devices are used for EVR to inform phy-
sicians on the cost implications of device selection.
METHODS
The general methods, clinical outcomes, and cost-
effectiveness of the OVER trial have been reported previ-
ously in detail.4,5 The study was approved by a central
human rights committee and the Institutional Review
Boards at each participating center. Informed consent was
obtained from all participants. Between October 2002 and
April 2008, 881 patients were randomized at 42 VAmedical
centers: 444 to EVR and 437 to open repair. There was no
statistically signiﬁcant difference between the groups in
major morbidity, reintervention, aneurysm-related hospital-
ization, or health-related quality of life.
The device system was selected and documented by the
local investigator before randomization, and so open control
patients correspond with each device cohort. Data were
excluded for two low-volume devices that were implanted
in only 13 patients. The clinical trial database of OVER pa-
tients was linked to national VA and Medicare databases to
obtain information on health care utilization and cost. The
device components used for each patient were recorded in
the OVER case report forms, and prices were obtained
from the VA’s National Patient Prosthetics Database. This
did not include backup devices that were not implanted.
Hospitalization costs of AAA repair were obtained from
the VA Decision Support System (DSS) National Data Ex-
tracts.8 The DSS combines data from accounting, payroll,
patient care, and administrative sources to calculate costs,
which can be categorized in six mutually exclusive cate-
gories: surgery, nursing, laboratory, radiology, pharmacy,
and others. Each of these includes ﬁxed direct costs thatare related to the direct provision of care and do not vary
by volume, such as clerical personnel and nursing supervisor
time, andﬁxed indirect costs that are indirectly related to care
and do not vary by volume, such as building maintenance,
housekeeping, engineering, and administration. These costs
are assigned per diem according to individual length of stay.
Local VA electronic medical records were used to iden-
tify VA utilization data, including other hospital stays,
outpatient visits, contract care, and outpatient medications
acquired from VA. These data were obtained from the VA
Medical SAS Inpatient and Outpatient Datasets extracted
from the National Patient Care Database, which captures
information from local electronic medical records.9,10 Fee
basis ﬁles captured care provided to VA patients by contract
providers outside of VA facilities.11
Nonrepair hospitalization costs were obtained from the
VA Health Economics Resource Center (HERC) average
cost data sets,12-14 which are modeled from Medicare
claims data and adjusted to costs using cost-to-charge ra-
tios from reports to the Center for Medicare and Medicaid
Services.12 Costs for nonacute hospital stays (eg, rehabilita-
tion, mental health, and long-term care) were calculated
from length of stay and average daily cost from the DSS
National Data Extracts. Costs for VA outpatient visits
were based on reimbursement rates of Medicare and other
payers. Prescriptions costs were based on the VA’s acquisi-
tion and dispensing costs from the VA DSS National Data
Extracts Pharmacy Datasets.15
Non-VA health care utilization was obtained from
Medicare claims data and from patient reports veriﬁed
with billing data from the facilities where care was
received. Costs were estimated by multiplying the Medi-
care charges by the hospital-speciﬁc cost-to-charge ra-
tios.16 Total health care costs were summed from all of
the above; that is, the VA and private-sector providers.
Costs were adjusted to 2008 United States dollars with
the Consumer Price Index.
AneuRxc
Difference (95% CI)
Zenith Excluder Zenith AneuRx Excluder AneuRx
88
9
14,300 (4200) 800 (100-1400) 100 (800 to 1100) 700 (1800 to 300)
38,900 (24,900) 3300 (3400 to 8800) 800 (8100 to 5400) 4100 (11,300 to 2800)
4800 (9600 to 17,100) 5800 (6900 to 18,800) 1000 (11,500 to 14,000)
72,400 (42,400)
61,900 (43,900, 82,500)
98
6
300 (18,800 to 24,800) 6500 (17,500 to 30,600) 6200 (17,800 to 25,300)
75,600 (84,100)
52,100 (34,700, 76,100)
3200 (27,200 to 11,600)
Table I. Continued.
Table II. Costs of hospitalization for abdominal aortic aneurysm (AAA) endovascular repair (EVR; n ¼ 431)
Itema Zenithb (n ¼ 166) Excluderc (n ¼ 177) AneuRxd (n ¼ 88)
Surgery bed section 37,600 (27,400) 32,400 (22,900) 37,900 (22,400)
Nursing cost category 6400 (11,300) 5500 (11,500) 6700 (11,400)
Intensive care units 2400 (5300) 2100 (6100) 2500 (5700)
Wards 900 (2000) 700 (1400) 900 (1500)
Othere 500 (1400) 400 (900) 400 (800)
Fixed indirect total 2500 (4100) 2300 (4600) 2800 (5200)
Fixed direct total 100 (300) 100 (200) 100 (300)
Surgery cost category 24,800 (8900) 22,100 (7200) 24,400 (8900)
Operating room 3400 (3500) 2900 (2400) 3400 (2400)
Surgical implants 14,400 (2600) 13,600 (3800) 14,300 (4200)
Anesthesia 1300 (1300) 1100 (1000) 1100 (1000)
Other 500 (1800) 500 (2400) 300 (1400)
Fixed indirect total 5000 (4700) 3700 (3000) 4900 (4700)
Fixed direct total 300 (300) 400 (400) 300 (300)
Radiology cost category 1800 (3500) 1000 (2200) 2500 (3700)
Laboratory cost category 900 (1600) 700 (1400) 700 (1400)
Pharmacy cost category 900 (1600) 800 (1800) 900 (2000)
Other cost category 2800 (6000) 2300 (4200) 2800 (4000)
Other bed sections 600 (2200) 2400 (13,200) 1000 (4800)
Total cost 38,100 (27,500) 34,800 (31,200) 38,900 (24,900)
Total cost, median (IQR) 33,200 (27,300-40,900) 29,700 (24,700-37,600) 32,700 (26,900-42,400)
IQR, Interquartile range.
aCosts are in United States dollars and are shown as means (standard deviation) except as indicated otherwise.
bCook Inc, Bloomington, Ind.
cW. L. Gore and Associates, Flagstaff, Ariz.
dMedtronic, Minneapolis, Minn.
eIncludes recovery room, stepdown unit, etc.
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tween patients randomized to endovascular and open
repair on an intention-to-treat basis, regardless of the
occurrence or type of the actual AAA repair. Total health
care costs include initial repair, nonacute care hospitaliza-
tion, nonrepair hospitalization, surveillance imaging, rein-
terventions, outpatient care, prescriptions, and non-VA
hospitalization costs. Mean, median, and interquartile
values are provided and are rounded to the nearest $100.
Calculation of 95% CIs used bias-corrected acceleratedbootstrapping procedures without assumption about the
data having a normal distribution. A sensitivity analysis
was conducted to evaluate for censoring because of differ-
ences in 2-year mortality rates by using Kaplan-Meier sam-
ple average estimators.
RESULTS
The mean cost (61 standard deviation) of the device,
initial hospital admission, and total health care costs at
2 years are presented in Table I. The device was 38% of
Table III. Costs of hospitalization for open abdominal aortic aneurysm (AAA) repair (n ¼ 423)
Itema Zenithb (n ¼ 175) Excluderc (n ¼ 150) AneuRxd (n ¼ 98)
Surgery bed section 42,400 (56,400) 40,000 (40,100) 38,000 (48,200)
Nursing cost category 17,700 (31,700) 15,900 (15,800) 14,200 (19,700)
Intensive care units 7100 (15,100) 6100 (7100) 6300 (11,700)
Wards 1500 (2600) 1300 (2800) 1200 (1300)
Othere 1300 (3000) 1600 (5200) 800 (1700)
Fixed indirect total 7300 (15,500) 6700 (6600) 5700 (8100)
Fixed direct total 500 (2000) 300 (600) 200 (300)
Surgery cost category 12,300 (10,100) 10,400 (6900) 12,100 (8700)
Operating room 4100 (3600) 3400 (2500) 4300 (3700)
Surgical implants 1500 (3300) 1200 (2600) 1200 (2700)
Anesthesia 1600 (1800) 1300 (1300) 1600 (1500)
Other 500 (1800) 400 (1500) 200 (1100)
Fixed indirect total 4300 (3900) 3500 (2400) 4200 (3600)
Fixed direct total 400 (500) 400 (500) 400 (400)
Radiology cost category 1400 (2700) 1100 (1900) 1300 (2600)
Laboratory cost category 2100 (3000) 2100 (3600) 1800 (3000)
Pharmacy cost category 2100 (3600) 3800 (14,400) 2400 (4100)
Other cost category 6900 (11,500) 6600 (8500) 6200 (14,200)
Other bed sections 2700 (13,000) 4000 (12,600) 900 (4300)
Total cost 45,100 (60,100) 44,000 (46,000) 38,900 (48,300)
Total cost, median (IQR) 30,300 (19,800-48,100) 31,800 (24,800-42,600) 28,400 (21,400-39,600)
IQR, Interquartile range.
aCosts are in United States dollars and are shown as means (standard deviation) except as indicated otherwise.
bCook Inc, Bloomington, Ind.
cW. L. Gore and Associates, Flagstaff, Ariz.
dMedtronic, Minneapolis, Minn.
eIncludes recovery room, stepdown unit, etc.
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greater variability in hospitalization and total health
care costs than the device costs. The source of variability
is typical of health care cost data often due to prolonged
inpatient admissions. When selected EVR device systems
were compared, no statistically signiﬁcant difference was
found in device, hospitalization, or total health care costs
at 2 years. There was no statistically signiﬁcant difference
between EVR and open repair when a speciﬁc device
system was selected, although mean total health care
costs were lower in each cohort, ranging from $3153
to $8333. Speciﬁc cost breakdowns are provided in
Tables II-V. The sensitivity analysis showed survival
adjusted costs were similar (Table VI).
CONCLUSIONS
Physicians are increasingly integrated with hospitals,
and reimbursement models are being piloted with
bundled payments and shared savings. Data abound on
clinical outcomes with different EVR systems, but cost
data to inform selection of devices are scant. In this
multicenter randomized trial, total health care costs after
2 years after repair were not signiﬁcantly different be-
tween EVR and open repair of AAA in the group as a
whole and when analyzed by the speciﬁc device selected
for EVR. Shorter hospital and intensive care stays result
in lower hospital costs with EVR compared with open
repair, despite the high cost of the endovascular grafts,
which account for almost two-ﬁfths of the hospitalization
cost. Devices are a substantial portion of hospitalizationcosts; however, there are also improvements in the model
of care of AAA patients that may reduce costs in the
$60,000 to $70,000 of total health care costs not spent
on the device, and these also represent large targets of
opportunity.
Mean hospitalization costs have been presented, which
informs decision making in a classic volume-based reim-
bursement system, such as a hospital diagnosis-related
group.17 Total health care costs have also been presented,
which helps guide decision making in a population health
environment, such as an all-risk capitated system and a
shared savings Accountable Care Organization. Device se-
lection does not have a statistically signiﬁcant effect on
downstream costs in the system for the next 2 years. This
suggests that other factors, such as longer-term clinical out-
comes and price should inform device selection.18,19
Limitations of this analysis have been discussed previ-
ously.5,17 The cost-accounting does not have granularity
and may miss some items: prerandomization evaluation;
equipment or supplies that are included in direct ﬁxed costs
but are only applicable to one treatment cohort, such as an
autologous blood salvage setup or a deployment handle for
a speciﬁc device; and backup device inventory that is not
implanted. There are some potential distortions related to
protocol-required testing that may not be part of current
clinical routines. These data are derived from 42 VA med-
ical centers and may not directly apply to other populations
in other health care systems. However, the VA is a large in-
tegrated health care system in the United States, providing
care to >6 million veterans20 to whom these results are
Table IV. Health care costs to 2 years after randomization in United States dollars for endovascular repair (EVR; n ¼ 431)
Itema Zenithb (n ¼ 166) Excluderc (n ¼ 177) AneuRxd (n ¼ 88)
Before AAA repair
VA costs
Acute inpatient care 700 (3400) 1000 (5300) 700 (3600)
Rehabilitation, mental health, and long-term care 0 (0) 0 (200) 0 (200)
Outpatient visits 900 (1600) 1000 (2100) 1100 (2300)
Outpatient pharmacy 100 (200) 100 (400) 100 (200)
Non-VA costs
Acute inpatient care 100 (1300) 0 (400) 900 (8300)
Nursing home 0 (0) 0 (0) 0 (0)
Outpatient visits 0 (300) 0 (300) 0 (0)
Other care 0 (0) 0 (500) 0 (100)
Total 1900 (4000) 2200 (6000) 2800 (12,000)
Median (IQR) 700 (200-1300) 600 (100-1600) 400 (0-1000)
AAA repair
Total, per randomized patient 38,100 (27,500) 34,800 (31,200) 39,000 (24,900)
Median (IQR) 33,100 (27,300-40,900) 29,700 (24,700-37,600) 32,700 (26,900-42,400)
Discharge after AAA repair to 30 days
VA costs
Acute inpatient care 1000 (5000) 1100 (4100) 1100 (4700)
Rehabilitation, mental health, and long-term care 0 (600) 0 (800) 100 (700)
Outpatient visits 900 (1000) 900 (800) 1200 (2400)
Outpatient pharmacy 100 (200) 100 (200) 100 (300)
Non-VA costs
Acute inpatient care 0 (200) 100 (800) 0 (200)
Nursing home 100 (700) 0 (500) 0 (0)
Outpatient visits 0 (100) 0 (300) 0 (100)
Other care 100 (400) 0 (100) 0 (0)
Total 2300 (5100) 2300 (4600) 2700 (5100)
Median (IQR) 1200 (300-2000) 1100 (300-1900) 1100 (300-2500)
30 days to 1 year
VA costs
Acute inpatient care 7100 (26,000) 6600 (25,000) 3600 (10,500)
Rehabilitation, mental health, and long-term care 1400 (10,100) 1500 (11,200) 600 (2900)
Outpatient visits 7000 (4500) 7200 (6600) 5800 (3300)
Outpatient pharmacy 1200 (1100) 1200 (1800) 1300 (2000)
Non-VA costs
Acute inpatient care 1400 (4900) 2000 (10,700) 1200 (4100)
Nursing home 0 (0) 700 (4900) 200 (1300)
Outpatient visits 800 (3900) 400 (1400) 600 (1900)
Other care 200 (800) 300 (1400) 300 (1000)
Total 19,100 (31,100) 19,800 (35,700) 13,500 (15,200)
Median (IQR) 9900 (6700-20,100) 8700 (5500-16,700) 9300 (5400-13,400)
Total at 1 year 61,400 (48,800) 59,100 (52,700) 57,900 (32,000)
Median (IQR) 49,600 (40,100-64,900) 43,800 (34,100-62,800) 49,000 (39,000-64,800)
AAA repair, 1 year to 2 year 0 (0) 0 (0) 0 (0)
1 year to 2 years, other
VA costs
Acute inpatient care 6100 (19,800) 3400 (13,700) 1400 (4300)
Rehabilitation, mental health, and long-term care 300 (4000) 700 (9400) 0 (0)
Outpatient visits 4800 (4600) 6100 (10,000) 6600 (11,400)
Outpatient pharmacy 1200 (1700) 1100 (2100) 1200 (1300)
Non-VA Costs
Acute inpatient care 2500 (12,500) 1700 (6200) 3300 (17,700)
Nursing home 200 (1300) 500 (2500) 1400 (9100)
Outpatient visits 1600 (9100) 600 (3100) 600 (2100)
Other care 200 (700) 300 (1200) 100 (500)
Total, 1 year to 2 years 16,800 (33,800) 14,400 (24,500) 14,600 (25,500)
Median (IQR) 6800 (2800-18,300) 6100 (2800-12,600) 6400 (2800-16,500)
Total at 2 years 78,200 (60,200) 73,500 (65,100) 72,400 (42,400)
Median (IQR) 62,000 (48,000-85,400) 54,100 (39,400-76,300) 61,900 (43,900-82,500)
AAA, Abdominal aortic aneurysm; IQR, interquartile range; VA, Veterans Administration.
aCosts are shown as means (standard deviation) except as indicated otherwise.
bCook Inc, Bloomington, Ind.
cW. L. Gore and Associates, Flagstaff, Ariz.
dMedtronic, Minneapolis, Minn.
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Table V. Health care costs to 2 years after randomization in United States dollars for open repair (n ¼ 423)
Itema Zenith (n ¼ 175)b Excluder (n ¼ 150)c AneuRx (n ¼ 98)d
Before AAA repair
VA costs
Acute inpatient care 1200 (6700) 600 (4000) 500 (1800)
Rehabilitation, mental health, and long-term care 0 (0) 0 (0) 0 (0)
Outpatient visits 1000 (1800) 1100 (3200) 900 (1600)
Outpatient pharmacy 100 (200) 100 (200) 100 (200)
Non-VA costs
Acute inpatient care 0 (0) 0 (0) 100 (600)
Nursing home 0 (0) 0 (0) 0 (0)
Outpatient visits 0 (0) 0 (100) 100 (900)
Other care 0 (0) 0 (200) 0 (100)
Total 2300 (7300) 1800 (7100) 1600 (3500)
Median (IQR) 800 (200-1200) 500 (0-1300) 400 (0-1400)
AAA repair
Total, per randomized patient 43,700 (59,000) 43,800 (46,100) 38,900 (48,300)
Median (IQR) 29,900 (19,000-47,600) 31,800 (24,800-42,600) 28,400 (21,400-39,600)
Discharge after AAA repair to 30 days
VA costs
Acute inpatient care 1400 (5700) 1700 (7500) 1400 (9100)
Rehabilitation, mental health, and long-term
care
400 (3500) 400 (2900) 300 (1200)
Outpatient visits 300 (400) 300 (600) 400 (900)
Outpatient pharmacy 100 (200) 100 (300) 100 (100)
Non-VA costs
Acute inpatient care 200 (1800) 100 (800) 600 (3100)
Nursing home 0 (300) 0 (200) 100 (500)
Outpatient visits 0 (200) 0 (100) 0 (100)
Other care 100 (300) 100 (400) 0 (100)
Total 2600 (6900) 2800 (9000) 2800 (9700)
Median (IQR) 400 (200-1200) 300 (100-1000) 500 (200-1100)
30 days to 1 year
VA costs
Acute inpatient care 5600 (25,600) 4200 (12,000) 3800 (14,300)
Rehabilitation, mental health, and long-term care 2400 (22,300) 1100 (6500) 1000 (5700)
Outpatient visits 4500 (4300) 5300 (5300) 5000 (5300)
Outpatient pharmacy 1000 (1500) 1700 (6300) 1000 (1000)
Non-VA costs
Acute inpatient care 2100 (8100) 2900 (13,100) 2900 (12,100)
Nursing home 400 (3500) 200 (1400) 1200 (6300)
Outpatient visits 500 (1500) 600 (2200) 500 (1400)
Other care 400 (1500) 300 (1200) 400 (1400)
Total 16,900 (48,000) 16,200 (24,700) 15,700 (27,600)
Median (IQR) 4900 (2500-12,800) 7900 (3500-15,600) 6300 (3300-14,300)
Total at 1 year 65,400 (10,2900) 64,600 (60,500) 59,100 (76,200)
Median (IQR) 43,500 (26,200-69,100) 46,700 (33,700-67,600) 41,100 (30,000-59,600)
AAA repair, 1 year to 2 years 1400 (15,900) 200 (1900) 0 (0)
1 year to 2 years, other
VA costs
Acute inpatient care 5400 (22,400) 4600 (15,200) 5900 (17,500)
Rehabilitation, mental health, and long-term care 600 (5300) 1000 (9300) 1100 (5600)
Outpatient visits 4600 (6900) 5600 (8500) 4900 (5300)
Out patient pharmacy 1100 (2200) 1500 (2700) 1100 (1000)
Non-VA costs
Acute inpatient care 2500 (9600) 2900 (21,300) 2100 (8400)
Nursing home 100 (800) 0 (400) 700 (3800)
Outpatient visits 800 (2400) 700 (3100) 400 (1000)
Other care 100 (800) 700 (3100) 300 (1100)
Total, 1 year to 2 years 16,600 (45,700) 17,200 (36,400) 16,500 (24,900)
Median (IQR) 5500 (2000-13,500) 5800 (2200-16,100) 6100 (2900-19,700)
Total at 2 years 82,100 (11,3800) 81,800 (84,500) 75,600 (84,100)
Median (IQR) 57,000 (36,100-85,400) 56,800 (39,600-88,800) 52,100 (34,700-76,100)
AAA, Abdominal aortic aneurysm; IQR, interquartile range; VA, Veterans Administration.
aCosts are shown as means (standard deviation) except as indicated otherwise.
bCook Inc, Bloomington, Ind.
cW. L. Gore and Associates, Flagstaff, Ariz.
dMedtronic, Minneapolis, Minn.
JOURNAL OF VASCULAR SURGERY
64 Matsumura et al January 2015
Table VI. Sensitivity analysis of survival adjusted cost
Survival adjusted cost at
2 years Zenith Excluder AneuRx
Difference
Zenith Excluder Zenith AneuRx Excluder AneuRx
EVR (n ¼ 431), No. 166 177 88
Total cost at 2 years, $ 80,800 75,400 73,000 5300 7800 2400
Open (n ¼ 423), No. 175 150 98
Total cost at 2 years, $ 85,000 84,700 75,400 300 9500 9300
EVR, Endovascular repair.
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commonly used in federally funded economic studies.
Finally, the VA has a central procurement process and
may have lower costs than non-VA users, and these ﬁnd-
ings may not apply in systems in which endovascular grafts
costs are substantially different from those in the OVER
trial. However, we have presented the data in a manner
that allows other systems to factor in their speciﬁc device
costs.
Endovascular aneurysm repair implant costs are sub-
stantial. When evaluating total health care system expendi-
tures, there is large individual variability in costs, and there
is no signiﬁcant difference at 2 years among systems or
when an individual system is compared with open repair.
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